NGM
Price:
$1.54
Market Cap:
$128.53M
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is...[Read more]
Industry
Biotechnology
IPO Date
2019-04-04
Stock Exchange
NASDAQ
Ticker
NGM
According to NGM Biopharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 69.72M. This represents a change of -42.49% compared to the average of 121.22M of the last 4 quarters.
The mean historical Enterprise Value of NGM Biopharmaceuticals, Inc. over the last ten years is 823.27M. The current 69.72M Enterprise Value has changed 746.83% with respect to the historical average. Over the past ten years (40 quarters), NGM's Enterprise Value was at its highest in in the March 2021 quarter at 2.06B. The Enterprise Value was at its lowest in in the December 2017 quarter at -25593000.00.
Average
823.27M
Median
753.14M
Minimum
12.05M
Maximum
1.93B
Discovering the peaks and valleys of NGM Biopharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 181.67%
Maximum Annual Enterprise Value = 1.93B
Minimum Annual Increase = -96.38%
Minimum Annual Enterprise Value = 12.05M
Year | Enterprise Value | Change |
---|---|---|
2023 | 12.05M | -96.38% |
2022 | 333.28M | -72.77% |
2021 | 1.22B | -36.52% |
2020 | 1.93B | 181.67% |
2019 | 684.40M | -23.83% |
2018 | 898.48M | 17.74% |
2017 | 763.08M | 2.67% |
The current Enterprise Value of NGM Biopharmaceuticals, Inc. (NGM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
523.06M
5-year avg
836.27M
10-year avg
823.27M
NGM Biopharmaceuticals, Inc.’s Enterprise Value is greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Instil Bio, Inc. (171.51M), greater than Achilles Therapeutics plc (-61068820.00), greater than NextCure, Inc. (25.04M), less than Assembly Biosciences, Inc. (90.35M), less than Erasca, Inc. (689.13M), less than Century Therapeutics, Inc. (138.60M), less than Keros Therapeutics, Inc. (1.58B), less than Monte Rosa Therapeutics, Inc. (284.72M), less than Nkarta, Inc. (340.55M), less than Lyell Immunopharma, Inc. (226.32M), less than Generation Bio Co. (210.95M), less than Sana Biotechnology, Inc. (1.08B), greater than Kezar Life Sciences, Inc. (30.16M), less than Mineralys Therapeutics, Inc. (490.57M), less than Foghorn Therapeutics Inc. (318.59M), less than C4 Therapeutics, Inc. (369.73M), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Prelude Therapeutics Incorporated (257.24M), less than Rezolute, Inc. (237.24M),
Company | Enterprise Value | Market cap |
---|---|---|
-6333315.00 | $8.20M | |
171.51M | $92.68M | |
-61068820.00 | $29.58M | |
25.04M | $39.73M | |
90.35M | $107.81M | |
689.13M | $807.96M | |
138.60M | $123.69M | |
1.58B | $1.97B | |
284.72M | $349.21M | |
340.55M | $375.37M | |
226.32M | $299.52M | |
210.95M | $145.50M | |
1.08B | $1.12B | |
30.16M | $40.82M | |
490.57M | $558.43M | |
318.59M | $416.63M | |
369.73M | $374.42M | |
-20511738.00 | $108.71M | |
257.24M | $266.87M | |
237.24M | $240.80M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NGM Biopharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NGM Biopharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is NGM Biopharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for NGM Biopharmaceuticals, Inc. (NGM)?
What is the 3-year average Enterprise Value for NGM Biopharmaceuticals, Inc. (NGM)?
What is the 5-year average Enterprise Value for NGM Biopharmaceuticals, Inc. (NGM)?
How does the current Enterprise Value for NGM Biopharmaceuticals, Inc. (NGM) compare to its historical average?